Denis Garceau
Chief Tech/Sci/R&D Officer presso BELLUS HEALTH
Profilo
Denis Garceau is currently a Director at Bellus Health (Innodia), Inc., Cepmed, and Centre d’Excellence en Recherche sur les Maladies Orphelines.
He previously held the position of Chief Scientific Officer at BELLUS Health, Inc. and Vice President-Drug Development at Neurochem (International) Ltd.
Dr. Garceau also has former experience as a Director at ViroChem Pharma, Inc. and as a Clinical Scientist & Product Team Leader at Hoechst Marion Roussel Ltd.
(United Kingdom).
He obtained a doctorate degree from the University of Montréal.
Posizioni attive di Denis Garceau
| Società | Posizione | Inizio |
|---|---|---|
| BELLUS HEALTH | Chief Tech/Sci/R&D Officer | - |
Bellus Health (Innodia), Inc.
 Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | Director/Board Member | - |
Neurochem (International) Ltd.
 Neurochem (International) Ltd. Miscellaneous Commercial ServicesCommercial Services Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland. | Corporate Officer/Principal | 01/03/1997 |
| Cepmed | Director/Board Member | - |
| Centre d’Excellence en Recherche sur les Maladies Orphelines | Director/Board Member | - |
Precedenti posizioni note di Denis Garceau
| Società | Posizione | Fine |
|---|---|---|
Hoechst Marion Roussel Ltd. (United Kingdom)
 Hoechst Marion Roussel Ltd. (United Kingdom) Pharmaceuticals: OtherHealth Technology Founded in 1994, Hoechst Marion Roussel Ltd. (United Kingdom) is a British pharmaceutical company that manufactures pharmaceutical products. Part of Sanofi, the private company is based in Guildford, UK. | Corporate Officer/Principal | - |
ViroChem Pharma, Inc.
 ViroChem Pharma, Inc. Pharmaceuticals: MajorHealth Technology ViroChem Pharma, Inc. provides antiviral drug research and development services. The company provides R&D services on HIV/AIDS and hepatitis C. It was founded on April 8, 2004 and is headquartered in Laval, Canada. | Director/Board Member | - |
Formazione di Denis Garceau
| University of Montréal | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 7 |
|---|---|
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
Hoechst Marion Roussel Ltd. (United Kingdom)
Hoechst Marion Roussel Ltd. (United Kingdom) Pharmaceuticals: OtherHealth Technology Founded in 1994, Hoechst Marion Roussel Ltd. (United Kingdom) is a British pharmaceutical company that manufactures pharmaceutical products. Part of Sanofi, the private company is based in Guildford, UK. | Health Technology |
Bellus Health (Innodia), Inc.
Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | Health Technology |
ViroChem Pharma, Inc.
ViroChem Pharma, Inc. Pharmaceuticals: MajorHealth Technology ViroChem Pharma, Inc. provides antiviral drug research and development services. The company provides R&D services on HIV/AIDS and hepatitis C. It was founded on April 8, 2004 and is headquartered in Laval, Canada. | Health Technology |
Neurochem (International) Ltd.
Neurochem (International) Ltd. Miscellaneous Commercial ServicesCommercial Services Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland. | Commercial Services |
| Cepmed | |
| Centre d’Excellence en Recherche sur les Maladies Orphelines |
- Borsa valori
- Insiders
- Denis Garceau
